landmark trials in ovarian cancer - saint agnes … care, education and research landmark trials in...
TRANSCRIPT
Health Care, Education and Research www.billingsclinic.com
Landmark Trials in Ovarian Cancer
Where we’ve been and where we’re headed…
Erin E. Stevens, MD Gynecologic Oncology
Billings Clinic Cancer Center February 28, 2015
Objectives
• To understand the current standard of care for treatment of ovarian cancer.
• Primary treatment • Surveillance • Recurrence treatment
• To identify clinical trials in development and future directions for research.
http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index
http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index
Incidence Rates by Race and Ethnicity in US (1999-2011)
http://www.cdc.gov/cancer/ovarian/statistics/race.htm
Death Rates by Race and Ethnicity (1999-2011)
http://www.cdc.gov/cancer/ovarian/statistics/race.htm
Incidence Rate by State (2011)
http://www.cdc.gov/cancer/ovarian/statistics/state.htm
Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population
Overview
• Primary Surgical Management & Staging • Primary Chemotherapy • Surveillance • Recurrent Chemotherapy Regimens
• Platinum Sensitive • Platinum Resistant
• Uncommon Ovarian Malignancies • Next Directions
Barakat RR, et al. (2013) Principles and Practice of Gynecologic Oncology.
Chemotherapy
Historical Perspective
How Did We Get to Carboplatin & Paclitaxel as Standard of Care?
Platinum Based Chemotherapy • Cyclophophamide, Doxorubicin, +/- Cisplatin
Omura, G et al. (1986) Cancer. 57:1725-30. GOG 47
Single agent HR = 1.01 (95% CI 0.81-1.26) Combination HR = 1.02 (95% CI 0.92 – 1.13) Overall HR = 1.02 (95% CI 0.93-1.12)
Cisplatin Carboplatin
Aabo, K et al. (1998) BriJ Cancer. 78(11):1479-1487
Taxane Based Chemotherapy • Cyclophosphamide/Cisplatin versus Paclitaxel/Cisplatin
McGuire WP et al. (1996) NEJM, 334(1)1-6. GOG111
Taxane Based Chemotherapy • Cisplatin versus Paclitaxel versus Combination
• Cisplatin better PFS but OS was not statistically different • Toxicities and completion rates favored combination
Muggia FM et al. (2000) J Clin Oncol. 18(1): 106-115. GOG 132
» Recurrent disease – 24 hour regimen
was to avoid hypersensitivity
– 3 hour had less myelosuppression
– No difference in response rates
Paclitaxel: 3 hour versus 24 hour
Eisenhauer EA et al. (1994) JCO 12(12): 2654-2666
» Docetaxel 60-75 mg/m2
– Less neurotoxicity – Greater myelotoxicity – Equivalent PFS and OS Vasey PA et al. (2004) J Natl Cancer Inst; 96:1682-1691
» Albumin-bound nab-Paclitaxel (Abraxane) – Has not been directly compared
» Microparticle bound paclitaxel (Xyotax) – GOG 212: study for consolidation therapy
Alternate Taxanes
Ovarian Cancer: Present Day • Landmark trials
– Standard Chemotherapy • GOG 172, JGOG, NACT
– Advanced Disease • MITO-7, 218, ICON7
– Recurrent Disease • Recent results: 262 • Current NCCN standard of care • Awaiting results: 212, 252
Ovarian Cancer: Armstrong IP
Ovarian Cancer: JGOG Dose Dense
Katsumata N et al (2013) Lancet 14(10):1020-6.
Ovarian Cancer: Neoadjuvant Chemotherapy
Vergote et al. (2010) NEJM 363:943-53.
Ovarian Cancer: MITO - 7
Addition of Bevacizumab in Primary Treatment Regimens
Barakat RR, et al. (2013) Principles and Practice of Gynecologic Oncology.
Ovarian Cancer: GOG 218
Ovarian Cancer: GOG 218
Ovarian Cancer: ICON7
Ovarian Cancer: ICON7
Suboptimally debulked patients
Ovarian Cancer: GOG 262
Ovarian Cancer: GOG 262
• Dose dense is superior to q3 week CT • Subanalysis **very underpowered**
• Addition of bevacizumab to q3 week regimen is near equivalent PFS to dose dense • 10 months without vs 14 months with
• Addition of bevacizumab in dose dense regimen did not have an increased PFS • 15 months both arms
Awaiting Results
• GOG 212 – Maintenance chemotherapy (12 months) of
taxol, CT-2103, or observation after complete clinical response to primary CT chemotherapy
• GOG 252 – Phase III Clinical Trial of Bevacizumab with
IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Epithelial Ovarian Cancer: Surveillance
» Double upper limit of normal on two occasions at least one week apart (GCIG Criteria)
» Often elevated 2-5 months prior to clinical relapse – Sensitivity: 62-94% – Specificity: 91-100%
Ovarian: CA125
CA125: Does Early Treatment Matter?
Rustin GJ (2010) Lancet. 326: 1155-1163.
» Bloating » Early satiety » Abdominal pain » Pelvic pain » Bowel habit changes » Urinary Urgency » Urinary Frequency
Ovarian: Symptoms
» Benefits of Routine Imaging – Diagnose asymptomatic recurrence – Higher rate of optimal secondary
cytoreductive surgery – May benefit overall survival
» Insufficient data to support routine use
Ovarian: Routine Imaging
Ovarian Cancer: Recurrent Disease
• All trials now focus on PFS • Nothing we have done in ovarian
cancer recurrent disease treatment has increased OS in the last 10 years
• Treating a patient at the time of biochemical or radiologic recurrence without presence of symptoms does not improve OS
» Carboplatin/Paclitaxel » Carboplatin alone » Carboplatin/Docetaxel » Carboplatin/Liposomal Doxorubicin » Carboplatin/Gemcitabine
Platinum Sensitive
» Phase II Trial q3 week dose » Overall response rate: 72% » Median PFS: 19 months » Patients with platinum-free interval >
12 months showed better PFS/OS
» Weekly dosing (D1,8,15 of q28d) » Overall response rate: 67% » Median PFS: not reported
Carboplatin/Docetaxel
Strauss HG et al. (2006) Gyn Oncol. 104:612-616.
Kushner DM et al. (2007) Gyn Oncol. 105:358-64.
Carboplatin/Liposomal Doxorubicin (CALYPSO)
Pujade-Lauraine E et al. (2010) JCO. 28(20)3323-29
» Randomization of Bevacizumab » 6-10 cycles of CG +/- bevacizumab followed
by maintenance bevacizumab/placebo
» Objective response rate: 57.4% vs 78.5%
» PFS: 8.4 vs 12.4 months » Favors addition of bevacizumab
Carboplatin/Gemcitabine (OCEANS)
Aghajanian C et al (2012) JCO. 30(17):2039-2045.
» Docetaxel » Oral Etoposide » Gemcitabine » Liposomal Doxorubicin* » Paclitaxel (weekly)* » Topotecan* » Bevacizumab
Platinum Resistant
* Addition of bevacizumab may be considered
» Platinum resistant » Dosed 100mg/m2
» Significant hematologic toxicities
» Response rate: 22.4% » Median PFS: 2.5 months
Docetaxel
Rose PG et al. (2003) Gyn Oncol. 88:130-135.
» Platinum resistant » Overall response rate: 29% » PFS: 20 weeks
Gemcitabine
Ferrandina G et al. (2008) JCO. 26(6):890-896.
» Platinum resistant » Overall response rate: 16% » PFS: 16 weeks
Liposomal Doxorubicin
Ferrandina G et al. (2008) JCO. 26(6):890-896.
» Weekly vs Conventional D1-5 » Clinical benefit rates: 47% vs 58%
» Benefit favors conventional regimen » Toxicity profile favors weekly
» Less hematologic toxicities
» Median PFS: 3.7 months » No difference between Tc or Tw
Topotecan (TOWER)
Sehouli J et al. (2011) JCO. 29(2):242-248.
» Platinum Resistant - Phase III » Randomization of Bevacizumab » Investigator Selected Regimen
» Liposomal Doxorubicin » Weekly Paclitaxel » Topotecan
» PFS 3.4 vs 6.7 months » Favors addition of bevacizumab
AURELIA (+Bevacizumab)
Pujade-Lauraine E et al (2014) JCO. 32(13):1302-8.
» Platinum resistant (83.7% primary) » Topotecan and/or Liposomal Doxorubicin
» Partial response: 15.9% » Median PFS: 4.4 months
» Recurrent disease (58% platinum res) » Response rate: 21% » Median PFS: 4.7 months
Bevacizumab (alone)
Cannistra SA et al (2007) JCO. 25(33):5180-5186.
Burger RA et al (2007) JCO. 25(33):5165-5171.
Next Directions
• Primary Treatment Trials – Dose-dense (or standard) CT with PARPi in
primary and maintenance setting • Placebo primary + maintenance • PARPi primary + placebo maintenance • PARPi primary + maintenance
– Neoadjuvant chemotherapy (NACT) • CT vs CT+rituximab x 3 cycles, followed by CRS,
followed by 3 cycles plus possible maintenance
Health Care, Education and Research www.billingsclinic.com
Thank You!